Daxor Corporation (NASDAQ: DXR) is a clinical-stage medical diagnostics company specializing in the accurate measurement of total blood volume and its constituent plasma and red blood cell components. Its proprietary BVA-100 system employs a radiolabeled albumin tracer to deliver precise, quantitative assessments of blood volume in a single test, allowing physicians to make more informed decisions in the management of cardiovascular, renal and hematologic disorders. Daxor’s platform is designed to improve patient outcomes by guiding fluid management in heart failure, anemia, polycythemia and other conditions where volume dysregulation is a critical factor.
The company’s primary product, the BVA-100, has obtained CE Mark approval in Europe and is in various stages of clinical and regulatory review in the United States. BVA testing is offered through a centralized reference laboratory model, with trained technologists performing assays and delivering detailed reports to ordering physicians. Daxor works closely with hospitals, heart failure clinics and specialty treatment centers to integrate BVA measurements into patient care pathways, supplementing traditional vital signs and imaging studies with objective volumetric data.
Daxor serves healthcare providers across North America and Europe, with a growing presence in key cardiology and nephrology markets. The company collaborates with academic medical centers on clinical studies aimed at validating the clinical utility of blood volume analysis for guiding therapy adjustments, optimizing diuretic use and reducing hospital readmissions. Daxor also engages with regulatory agencies, professional societies and patient advocacy groups to promote awareness of volume management and to facilitate the adoption of its technology in routine practice.
Founded in 1998 and headquartered in New York City, Daxor has evolved from early research initiatives at leading academic institutions into a commercial-stage entity focused on expanding access to BVA testing. James H. Gilbaugh Jr., Chairman and Chief Executive Officer, leads a management team with decades of combined experience in medical devices, diagnostics and regulatory affairs. Under their guidance, Daxor continues to advance its product pipeline and pursue strategic partnerships aimed at extending the reach of its blood volume analysis platform.
AI Generated. May Contain Errors.
Free DXR Stock Alerts